14.73 USD
▲+0.65+8.95%
盘后 13.51 -0.11%
2026-08-03
市值
$725.42M
市盈率
—
EPS
-168.16
股息率
—
52 周区间
8.75 – 17.82
成交量
87.47K
Beta
—
目标价
33.00
52W 低 8.7552W 高 17.82
价格走势
公司简介
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 cli...